December 11, 2003

Francesco Bellini:
2003 Personnality of the year in Business Category

- Neurochem, Inc. (NASDAQ: NRMX, TSX: NRM) - Dr. Francesco Bellini, chairman and CEO of Neurochem, has been named Personality of the Year for 2003, in the Business category, by Cyberpresse.ca, a Montreal-based news Website.

Cyberpresse selected Dr. Bellini because the value of Neurochem's shares has more than tripled in the past year, making it the best-performing stock in Quebec this year.

In explaining the choice, Cyberpresse added: "There are several reasons for the strong performance by Neurochem's shares: first, there are the very positive consecutive results in clinical trials of its drug against Alzheimer's disease; then, there was the company's listing on NASDAQ, and lastly, there is Dr. Bellini's reputation. His former company, Biochem Pharma, discovered the AIDS drug, 3TC, in the late 1980s."

Dr. Bellini said he was very proud to receive this honour and insisted that Neurochem owes its success to its management team and employees. "Without a good business strategy based on the talents of all of our staff, our company could not have distinguished itself as it is now doing," he said.

About Neurochem

Neurochem is focused on the development and commercialization of innovative therapeutics for neurological disorders. The Company's staged pipeline of proprietary, disease-modifying, oral products addresses critical unmet medical needs. Fibrillex™, designated an orphan drug, is in a Phase II/III clinical trial for AA amyloidosis. Alzhemed™ has completed a Phase II clinical trial for the treatment of Alzheimer's Disease. Cerebril™ is in a Phase II trial for the prevention of hemorrhagic stroke caused by cerebral amyloid angiopathy. For additional information on Neurochem, please visit our website at: (www.neurochem.com).

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond Neurochem's control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which Neurochem does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation as well as other risks included in public filings of Neurochem. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance on the forward-looking statements included in this news release.

These statements speak only as of the date made and Neurochem is under no obligation and disavows any intention to update or revise such statements as a result of any event, circumstances or otherwise.

For further Information, please contact:
Dr. Lise Hébert
Vice President, Corporate Communications
lhebert@neurochem.com

275 Armand-Frappier
Laval (Quebec)
H7V 4A7
Tel: (450) 680-4500
Fax: (450) 680-4501

Our site is best viewed with IE4+ at a resolution of 1024×768.
All contents copyright © 1998-2007 Neurochem Inc.
Terms, Conditions and Legal Notice.